Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 6/14/2017
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||- / 1||UN / UN|
Administered by: Unknown Purchased by: Unknown
Symptoms: Chronic fatigue syndrome, Dizziness, Fatigue, Tachycardia, Postural orthostatic tachycardia syndrome
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? Yes
Current Illness: Routine childhood immunisation
Diagnostic Lab Data:
CDC 'Split Type': GB0095075131702GBR001295
Write-up:This spontaneous report as received from a consumer via the Agency (HA # EYC 00152376) refers to a 15 year old female patient. The patient''s medical history, concurrent conditions and concomitant medications were not reported. In 2013, the patient was vaccinated with the first dose of GARDASIL (parenteral; dose, lot # and expiration date were not reported) as routine childhood immunisation. In 2014, the patient was vaccinated with the second dose of GARDASIL (parenteral; dose, lot # and expiration date were not reported). On 23-FEB-2016, the patient experienced chronic fatigue syndrome (CFS) and postural orthostatic tachycardia syndrome (POTS). On an unknown date, the patient experienced dizziness. Seek advice details: tachycardia, dizziness and fatigue. The patient had a visit to accident and emergency 3 times. The patient had seen pediatrician and cardiologist and was waiting for nuclear magnetic resonance imaging (MRI) on heart. The outcome of the adverse events of chronic fatigue syndrome (CFS) and postural orthostatic tachycardia syndrome (POTS) was reported as not recovered. The outcome of dizziness was unknown. The relatedness between the adverse events and GARDASIL was not provided. The Agency considered the adverse events to be medically significant and disabling.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166